Rationale. The SCOR program is highly dependent upon the generation and maintenance of transgenic mice for the study of lung development and disease. This Core is designed to take advantage of established expertise in the generation of the transgenic mice used for the study of lung disease and for gene ablation studies that will be required for the present SCOR projects. Likewise, maintenance of pathogen-free, wild-type and transgenic lines will be critical for supplying genotyped mice for the various projects. This Core will both generate new transgenic lines and gene targeted mice, as well as maintain breeding and genotype analysis for the transgenic mice as required for the individual projects and investigators. This Core will: 1. provide animal husbandry, breeding, tail clip, Southern blot, PCR analysis for the mouse lines required for the SCOR projects. 2. generate all new transgenic lines described in the protocols by pronuclear injection and blastocyst injection for gene targeting. 3. Facilitate maintenance, breeding and surveillance of the transgenic animal models. 4. Monitor and facilitate oxygen exposure chambers and viral exposure protocols. 5. Develop new transgenic models for site-specific conditional expression of transgenes in the lung. The animals will be maintained in filtered-barrier caging in a pathogen-free facility at the Children?s Hospital Research Foundation under the direction of Gary Keller, D.V.M. This animal care program includes the use of sentinel mice and careful ongoing serological and pathologic surveillance for identification of pathogens. Such surveillance will be critical in the evaluation of lung disease in our various transgenic models and be necessary for the interpretation of genetic vs. environmental effects on lung development and repair following injury.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL056387-07
Application #
6644994
Study Section
Project Start
2002-08-01
Project End
2003-07-31
Budget Start
Budget End
Support Year
7
Fiscal Year
2002
Total Cost
$219,976
Indirect Cost
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Hahn, Andrew D; Higano, Nara S; Walkup, Laura L et al. (2017) Pulmonary MRI of neonates in the intensive care unit using 3D ultrashort echo time and a small footprint MRI system. J Magn Reson Imaging 45:463-471
Korsten, Peter; Strohmayer, Katharina; Baughman, Robert P et al. (2016) Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach. Clin Pulm Med 23:67-75
Lammi, Matthew R; Baughman, Robert P; Birring, Surinder S et al. (2015) Outcome Measures for Clinical Trials in Interstitial Lung Diseases. Curr Respir Med Rev 11:163-174
Wert, Susan E; Whitsett, Jeffrey A; Nogee, Lawrence M (2009) Genetic disorders of surfactant dysfunction. Pediatr Dev Pathol 12:253-74
Perl, Anne-Karina T; Gale, Emily (2009) FGF signaling is required for myofibroblast differentiation during alveolar regeneration. Am J Physiol Lung Cell Mol Physiol 297:L299-308
Bridges, James P; Xu, Yan; Na, Cheng-Lun et al. (2006) Adaptation and increased susceptibility to infection associated with constitutive expression of misfolded SP-C. J Cell Biol 172:395-407
Bullard, Janine E; Wert, Susan E; Whitsett, Jeffrey A et al. (2005) ABCA3 mutations associated with pediatric interstitial lung disease. Am J Respir Crit Care Med 172:1026-31
Shannon, John M; Hyatt, Brian A (2004) Epithelial-mesenchymal interactions in the developing lung. Annu Rev Physiol 66:625-45
Akeson, A L; Brooks, S K; Thompson, F Y et al. (2001) In vitro model for developmental progression from vasculogenesis to angiogenesis with a murine endothelial precursor cell line, MFLM-4. Microvasc Res 61:75-86
Akeson, A L; Wetzel, B; Thompson, F Y et al. (2000) Embryonic vasculogenesis by endothelial precursor cells derived from lung mesenchyme. Dev Dyn 217:23-Nov